Vanda Pharmaceuticals Inc. (VNDA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	215.7M	216.1M	198.8M	192.6M	254.4M
Cost of Revenue	15.5M	13.0M	11.3M	14.8M	24.3M
Gross Profit	200.2M	203.1M	187.5M	177.8M	230.1M
Operating Expenses
R&D Expense	117.0M	109.3M	74.4M	76.8M	85.8M
SG&A Expense	263.4M	238.0M	146.4M	112.9M	136.5M
General & Admin Expense	71.8M	—	144.5M	112.4M	133.9M
Selling & Marketing Expense	—	—	1.9M	500.0K	2.6M
Other Expenses	5.5M	7.0M	7.3M	2.1M	1.5M
Total Operating Expenses	385.9M	354.2M	228.1M	191.8M	223.8M
Cost and Expenses	401.4M	367.3M	239.4M	206.6M	248.1M
Operating Income (EBIT)	(185.7M)	(151.2M)	(40.7M)	(14.0M)	6.3M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	8.5M	12.5M	17.7M	20.3M	5.0M
Non-Operating Income (excl Interest)	(5.6M)	(12.5M)	(17.7M)	(20.3M)	(5.0M)
EBT (Pre-Tax Income)	(177.2M)	(138.6M)	(22.9M)	6.3M	11.3M
Income Tax Expense	97.7M	81.8M	(4.0M)	3.8M	5.0M
Bottom Line
Net Income	(274.9M)	(220.5M)	(18.9M)	2.5M	6.3M
Earnings from Cont. Ops	(274.9M)	(220.5M)	(18.9M)	2.5M	6.3M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(274.9M)	(220.5M)	(18.9M)	2.5M	6.3M
Per Share
Basic EPS	($4.63)	($3.74)	($0.32)	$0.04	$0.11
Diluted EPS	($4.63)	($3.74)	($0.32)	$0.04	$0.11
Revenue Per Share	$3.58	$3.67	$3.42	$3.36	$4.51
Shares
Basic Shares Outstanding	60.2M	58.9M	58.1M	57.4M	56.5M
Diluted Shares Outstanding	60.2M	58.9M	58.1M	57.6M	57.0M
Profitability Metrics
EBITDA	(166.6M)	(126.7M)	(14.8M)	9.3M	14.0M
D&A	13.4M	11.9M	8.1M	3.0M	2.7M
EBIT	(180.1M)	(138.6M)	(22.9M)	6.3M	11.3M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026